- Home
- APTO vs ALZN Comparison
APTO vs ALZN Comparison
Compare APTO & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APTO
- ALZN
- Stock Information
- Founded
- APTO 1986
- ALZN 2016
- Country
- APTO Canada
- ALZN United States
- Employees
- APTO N/A
- ALZN N/A
- Industry
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- APTO Health Care
- ALZN Health Care
- Exchange
- APTO Nasdaq
- ALZN Nasdaq
- Market Cap
- APTO 6.8M
- ALZN 6.1M
- IPO Year
- APTO N/A
- ALZN 2021
- Fundamental
- Price
- APTO $1.71
- ALZN $1.04
- Analyst Decision
- APTO Strong Buy
- ALZN Strong Buy
- Analyst Count
- APTO 3
- ALZN 1
- Target Price
- APTO $112.00
- ALZN $20.00
- AVG Volume (30 Days)
- APTO 58.8K
- ALZN 212.9K
- Earning Date
- APTO 05-13-2025
- ALZN 03-10-2025
- Dividend Yield
- APTO N/A
- ALZN N/A
- EPS Growth
- APTO N/A
- ALZN N/A
- EPS
- APTO N/A
- ALZN N/A
- Revenue
- APTO N/A
- ALZN N/A
- Revenue This Year
- APTO N/A
- ALZN $322.64
- Revenue Next Year
- APTO N/A
- ALZN N/A
- P/E Ratio
- APTO N/A
- ALZN N/A
- Revenue Growth
- APTO N/A
- ALZN N/A
- 52 Week Low
- APTO $1.35
- ALZN $0.64
- 52 Week High
- APTO $50.10
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- APTO 26.12
- ALZN 58.05
- Support Level
- APTO $3.20
- ALZN $0.95
- Resistance Level
- APTO $3.43
- ALZN $1.13
- Average True Range (ATR)
- APTO 0.35
- ALZN 0.10
- MACD
- APTO -0.06
- ALZN 0.02
- Stochastic Oscillator
- APTO 13.69
- ALZN 81.52
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.